Who Will Benefit from the Darunavir Single-Tablet Regimen for HIV?
Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.
Magda Opsomer, MD, director and clinical leader of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies, Belgium, reveals who will benefit from the darunavir single-tablet HIV regimen.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Recent Videos
Related Content
